Table 2.
Study Conditions, Guideline-Recommended Medications and Physical Function (All percentages are column percentages)
| Study Condition: | Atrial Fibrillation | Coronary Artery Disease | Depression | Diabetes | Heart Failure | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Guideline-Recommended Medications: | N=662 | N=1658 | N=611 | N=1668 | N=516 | |||||
| n | % | n | % | n | % | n | % | n | % | |
| One or more | 517 | 78.1 | 1531 | 92.3 | 249 | 40.8 | 1465 | 87.8 | 455 | 88.2 |
| Beta-blocker | 424 | 64.0 | 1084 | 65.4 | - | - | - | - | 370 | 71.8 |
| Non-dihydropyridine Calcium channel blocker | 100 | 15.2 | - | - | - | - | - | - | - | - |
| Metformin | - | - | - | - | - | - | 638 | 38.2 | - | - |
| Renin-angiotensin blocker | - | - | 975 | 58.8 | - | - | 1009 | 60.5 | 360 | 69.8 |
| Selective serotonin reuptake inhibitor | - | - | - | - | 249 | 40.8 | - | - | - | - |
| Statin | - | - | 1101 | 66.4 | - | - | 1025 | 61.5 | - | - |
| Physical Function at Baseline a | ||||||||||
| Overall Sample: | ||||||||||
| Able to perform 5 | 559 | 84.5 | 1408 | 85.0 | 486 | 79.5 | 1437 | 86.1 | 402 | 77.9 |
| Able to perform 4 | 78 | 11.8 | 188 | 11.3 | 86 | 14.1 | 162 | 9.7 | 76 | 14.7 |
| Able to perform 1–3 | 25 | 3.7 | 62 | 3.7 | 39 | 6.4 | 69 | 4.1 | 38 | 7.4 |
| Low Polypharmacy: b | ||||||||||
| Able to perform 5 | 344 | 88.2 | 824 | 89.0 | 271 | 87.1 | 837 | 89.7 | 176 | 83.0 |
| Able to perform 4 | 36 | 9.2 | 75 | 8.1 | 25 | 8.0 | 67 | 7.2 | 25 | 11.8 |
| Able to perform 1–3 | 10 | 2.6 | 27 | 2.9 | 15 | 4.8 | 29 | 3.1 | 11 | 5.2 |
| High Polypharmacy: b | ||||||||||
| Able to perform 5 | 215 | 79.0 | 584 | 79.8 | 215 | 71.7 | 600 | 81.6 | 226 | 74.3 |
| Able to perform 4 | 42 | 15.4 | 113 | 15.4 | 61 | 20.3 | 95 | 12.9 | 51 | 16.8 |
| Able to perform 1–3 | 15 | 5.6 | 35 | 4.8 | 24 | 8.0 | 40 | 5.5 | 27 | 8.9 |
| Unadjusted decline c in physical function (Percent declined and 95% confidence interval). | ||||||||||
| Overall Sample: | 20.6 (14.9, 26.2) | 24.1 (20.4, 27.9) | 35.1 (27.5, 42.8) | 23.4 (19.7, 27.0) | 35.4 (26.3, 44.5) | |||||
| Low Polypharmacy b | 17.0 (10.1, 23.9) | 16.9 (13.0, 20.9) | 34.6 (24.0, 45.2) | 16.6 (12.3, 20.9) | 25.8 (13.6, 37.9) | |||||
| High Polypharmacy b | 25.9 (16.4, 35.5) | 35.4 (28.3, 42.5) | 35.7 (24.7, 46.7) | 32.4 (26.2, 38.7) | 43.5 (30.3, 56.8) | |||||
a
Based on the number of activities (writing/handling objects, extending arms above shoulder, stooping/kneeling/crouching, lifting/carrying 10 pounds, walking ¼ mile or 2–3 blocks) that the respondent was able to do.
b
Low polypharmacy defined as < 7 and High Polypharmacy as >=7 concomitant medications.
c
Decline in physical function defined as a decrease in the number of activities the participant was able to perform as compared to the baseline. Respondents who could not do any of the 5 activities were excluded since they could not decline. Product-limit estimates.